CVS Caremark Corp. (NYSE: CVS) said Tuesday that it has developed a pact with Generation Health Inc. in order to do more genetic research, according to Associated Press.
The company said is planning to do more research on the interactions between a person's genes and the effectiveness of the drugs he or she is taking,
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
CVS said it is taking a minority stake in "genetic benefit management company" Generation Health. It said the testing will help clients of the Caremark pharmacy benefits management business whose current medications are not working, or are causing unpleasant side effects.
Research on the interaction between genes and medication is called pharmacogenomics, and CVS is hoping it can use information from the testing to determine which drugs will work on which patients. If patients to begin their treatment with drugs that work rather than switching, that reduces medical costs.
Services from the partnership will be introduced to Caremark clients starting in the second quarter of 2010, and the partnership will focus on drugs for cancer, heart disease, HIV and other areas at first. The Woonsocket, R.I., company said it already does some pharmacogenomic testing in its specialty drug business, which focuses on dispensing drugs for chronic and complex illnesses such as diabetes.
Financial terms of the partnership between CVS and Generation Health were not disclosed. CVS Chief Medical Officer Troyen Brennan will join the board of Generation Health, which is based in Upper Saddle River, N.J.
At Tuesday’s close, CVS shares fell $1.04, or 3.4 percent, to $29.86.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
